Infliximab is superior to other biological agents for treatment of active ulcerative colitis: A meta-analysis

World Journal of Gastroenterology

Volumn 21, Issue 19, 2015, Pages 6044-6051

  Mei, Wei Qun ^a   Hu, Hui Zhen ^a   Liu, Ying ^a   Li, Zhi Chen ^a   Wang, Wei Guo ^a  

^a The 117th Hospital of Chinese PLA   (China)

Author keywords

Biological agents; Drug safety; Efficacy; Meta analysis; Ulcerative colitis

Indexed keywords

ADALIMUMAB; BIOLOGICAL PRODUCT; GOLIMUMAB; INFLIXIMAB; PLACEBO; VEDOLIZUMAB; IMMUNOSUPPRESSIVE AGENT; TUMOR NECROSIS FACTOR;

ARTICLE; BAYES THEOREM; CLINICAL EFFECTIVENESS; CLINICAL TRIAL (TOPIC); DRUG EFFICACY; DRUG SAFETY; HUMAN; MAINTENANCE THERAPY; META ANALYSIS; RANDOMIZED CONTROLLED TRIAL (TOPIC); RECTUM HEMORRHAGE; REMISSION; TREATMENT RESPONSE; ULCER HEALING; ULCERATIVE COLITIS; UNSPECIFIED SIDE EFFECT; ADULT; ANTAGONISTS AND INHIBITORS; COLITIS, ULCERATIVE; COLON; DRUG EFFECTS; IMMUNOLOGY; INTESTINE MUCOSA; MIDDLE AGED; ODDS RATIO; PATHOLOGY; RISK FACTOR; TIME FACTOR; TREATMENT OUTCOME; WOUND HEALING;

ADULT; BIOLOGICAL PRODUCTS; COLITIS, ULCERATIVE; COLON; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INFLIXIMAB; INTESTINAL MUCOSA; MIDDLE AGED; ODDS RATIO; REMISSION INDUCTION; RISK FACTORS; TIME FACTORS; TREATMENT OUTCOME; TUMOR NECROSIS FACTOR-ALPHA; WOUND HEALING;

EID: 84929649856     PISSN: 10079327     EISSN: 22192840     Source Type: Journal    
DOI: 10.3748/wjg.v21.i19.6044     Document Type: Article

References (21)

1. Ochsenkühn T, D'Haens G. Current misunderstandings in the management of ulcerative colitis. Gut 2011;60:1294-1299 [PMID: 21504997 DOI: 10.1136/gut.2010.218180]
2. Stange EF, Travis SP, Vermeire S, Reinisch W, Geboes K, Barakauskiene A, Feakins R, Fléjou JF, Herfarth H, Hommes DW, Kupcinskas L, Lakatos PL, Mantzaris GJ, Schreiber S, Villanacci V, Warren BF. European evidence-based Consensus on the diagnosis and management of ulcerative colitis: Definitions and diagnosis. J Crohns Colitis 2008;2:1-23 [PMID: 21172194 DOI: 10.1016/j.crohns.2007.11.001]
3. Danese S, Fiorino G, Peyrin-Biroulet L, Lucenteforte E, Virgili G, Moja L, Bonovas S. Biological agents for moderately to severely active ulcerative colitis: a systematic review and network metaanalysis. Ann Intern Med 2014;160:704-711 [PMID: 24842416 DOI: 10.7326/M13-2403]
4. Sonu I, Lin MV, Blonski W, Lichtenstein GR. Clinical pharmacology of 5-ASA compounds in inflammatory bowel disease. Gastroenterol Clin North Am 2010;39:559-599 [PMID: 20951918 DOI: 10.1016/j.gtc.2010.08.011]
5. Eugene C. Ulcerative colitis practice guidelines in adults. Clin Res Hepatol Gastroenterol 2012;36:107-109 [PMID: 22236738 DOI: 10.1016/j.clinre.2011.12.005]
6. Lichtenstein GR, Abreu MT, Cohen R, Tremaine W. American Gastroenterological Association Institute medical position statement on corticosteroids, immunomodulators, and infliximab in inflammatory bowel disease. Gastroenterology 2006;130:935-939 [PMID: 16530531 DOI: 10.1053/j.gastro.2006.01.047]
7. Samaan MA, Bagi P, Vande Casteele N, D'Haens GR, Levesque BG. An update on anti-TNF agents in ulcerative colitis. Gastroenterol Clin North Am 2014;43:479-494 [PMID: 25110254 DOI: 10.1016/j.gtc.2014.05.006]
8. Gilroy L, Allen PB. Is there a role for vedolizumab in the treatment of ulcerative colitis and Crohn's disease? Clin Exp Gastroenterol 2014;7:163-172 [PMID: 24899819 DOI: 10.2147/CEG. S45261]
9. Induction and maintenance therapy with vedolizumab, a novel biologic therapy for ulcerative colitis. Gastroenterol Hepatol (N Y) 2014;10:64-66 [PMID: 24799843]
10. Mills EJ, Thorlund K, Ioannidis JP. Demystifying trial networks and network meta-analysis. BMJ 2013;346:f2914 [PMID: 23674332 DOI: 10.1136/bmj.f2914]
11. Salanti G, Higgins JP, Ades AE, Ioannidis JP. Evaluation of networks of randomized trials. Stat Methods Med Res 2008;17:279-301 [PMID: 17925316 DOI: 10.1177/0962280207080643]
12. Sandborn WJ, Feagan BG, Marano C, Zhang H, Strauss R, Johanns J, Adedokun OJ, Guzzo C, Colombel JF, Reinisch W, Gibson PR, Collins J, Jarnerot G, Hibi T, Rutgeerts P. Subcutaneous golimumab induces clinical response and remission in patients with moderate-to-severe ulcerative colitis. Gastroenterology 2014;146:85-95; quiz e14-e15 [PMID: 23735746 DOI: 10.1053/j.gastro.2013.05.048]
13. Sandborn WJ, Feagan BG, Marano C, Zhang H, Strauss R, Johanns J, Adedokun OJ, Guzzo C, Colombel JF, Reinisch W, Gibson PR, Collins J, Jarnerot G, Rutgeerts P. Subcutaneous golimumab maintains clinical response in patients with moderatetosevere ulcerative colitis. Gastroenterology 2014;146:96-109. e1 [PMID: 23770005 DOI: 10.1053/j.gastro.2013.06.010]
14. Feagan BG, Rutgeerts P, Sands BE, Hanauer S, Colombel JF, Sandborn WJ, Van Assche G, Axler J, Kim HJ, Danese S, Fox I, Milch C, Sankoh S, Wyant T, Xu J, Parikh A. Vedolizumab as induction and maintenance therapy for ulcerative colitis. N Engl J Med 2013;369:699-710 [PMID: 23964932 DOI: 10.1056/NEJMoa1215734]
15. Callhoff J, Sieper J, Weis A, Zink A, Listing J. Efficacy of TNFα blockers in patients with ankylosing spondylitis and nonradiographic axial spondyloarthritis: a meta-analysis. Ann Rheum Dis 2015;74:1241-1248 [PMID: 24718959 DOI: 10.1136/annrheumdis-2014-205322]
16. Rutgeerts P, Sandborn WJ, Feagan BG, Reinisch W, Olson A, Johanns J, Travers S, Rachmilewitz D, Hanauer SB, Lichtenstein GR, De Villiers WJ, Present D, Sands BE, Colombel JF. Infliximab for induction and maintenance therapy for ulcerative colitis. N Engl J Med 2005;353:2462-2476 [PMID: 16339095 DOI: 10.1056/NEJMoa050516]
17. Feagan BG, Reinisch W, Rutgeerts P, Sandborn WJ, Yan S, Eisenberg D, Bala M, Johanns J, Olson A, Hanauer SB. The effects of infliximab therapy on health-related quality of life in ulcerative colitis patients. Am J Gastroenterol 2007;102:794-802 [PMID: 17324131 DOI: 10.1111/j.1572-0241.2007.01094.x]
18. Sandborn WJ, Rutgeerts P, Feagan BG, Reinisch W, Olson A, Johanns J, Lu J, Horgan K, Rachmilewitz D, Hanauer SB, Lichtenstein GR, De Villiers WJ, Present D, Sands BE, Colombel JF. Colectomy rate comparison after treatment of ulcerative colitis with placebo or infliximab. Gastroenterology 2009;137:1250-1260; quiz 1520 [PMID: 19596014 DOI: 10.1053/j.gastro.2009.06.061]
19. Suzuki Y, Motoya S, Hanai H, Matsumoto T, Hibi T, Robinson AM, Mostafa NM, Chao J, Arora V, Camez A, Thakkar RB, Watanabe M. Efficacy and safety of adalimumab in Japanese patients with moderately to severely active ulcerative colitis. J Gastroenterol 2014;49:283-294 [PMID: 24363029 DOI: 10.1007/s00535-013-0922-y]
20. Sandborn WJ, Van Assche G, Reinisch W, Colombel JF, D'Haens G, Wolf DC, Kron M, Tighe MB, Lazar A, Thakkar RB. Adalimumab induces and maintains clinical remission in patients with moderatetosevere ulcerative colitis. Gastroenterology 2012;142:257-265. e1-e3 [PMID: 22062358 DOI: 10.1053/j.gastro.2011.10.032]
21. Reinisch W, Sandborn WJ, Hommes DW, D'Haens G, Hanauer S, Schreiber S, Panaccione R, Fedorak RN, Tighe MB, Huang B, Kampman W, Lazar A, Thakkar R. Adalimumab for induction of clinical remission in moderately to severely active ulcerative colitis: results of a randomised controlled trial. Gut 2011;60:780-787 [PMID: 21209123 DOI: 10.1136/gut.2010.221127]